Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

r		1		
Accounting Title	2016/3rd	2015/3rd	2016/01/01To2016/09/30	2015/01/01To2015/09/30
Income Statement				
Total operating revenue	87,216	57,444	127,245	77,193
Total operating costs	45,319	26,876	115,327	68,899
Gross profit (loss) from operations	41,897	30,568	11,918	8,294
Gross profit (loss) from operations	41,897	30,568	11,918	8,294
Operating expenses				
Total selling expenses	2,231	637	6,691	2,439
Total administrative expenses	7,407	5,876	22,218	23,547
Total research and development expenses	63,429	38,111	152,415	101,621
Total operating expenses	73,067	44,624	181,324	127,607
Net operating income (loss)	-31,170	-14,056	-169,406	-119,313
Non-operating income and expenses				
Total other income	12,559	3,263	40,605	24,189
Other gains and losses, net	-4,665	6,808	-6,843	1,387
Total non-operating income and expenses	7,894	10,071	33,762	25,576
Profit (loss) from continuing operations before tax	-23,276	-3,985	-135,644	-93,737
Total tax expense (income)	69	174	268	472
Profit (loss) from continuing operations	-23,345	-4,159	-135,912	-94,209
Profit (loss)	-23,345	-4,159	-135,912	-94,209
Total comprehensive income	-23,345	-4,159	-135,912	-94,209
Basic earnings per share				
Total basic earnings per share	-0.21	-0.04	-1.24	-0.85

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

Accounting Title	2016/01/01To2016/09/30	2015/01/01To2015/09/30
Statements of Cash Flows		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-135,644	-93,737
Profit (loss) before tax	-135,644	-93,737
Depreciation expense	29,435	25,196
Amortization expense	743	987
Interest income	-6,235	-10,683
Share-based payments	9,530	436
Loss (gain) on disposal of property, plan and equipment	149	
Impairment loss on non-financial assets	592	74
Other adjustments to reconcile profit (loss)	0	
Total adjustments to reconcile profit (loss)	34,214	16,010
Decrease (increase) in notes receivable	71	10,010
Decrease (increase) in notes receivable Decrease (increase) in accounts receivable	6,525	956
Decrease (increase) in accounts receivable Decrease (increase) in accounts receivable due from related parties		
	-6,495	4,927
Decrease (increase) in other receivable	-10,446	3,461
Decrease (increase) in inventories	-16,588	-4,558
Decrease (increase) in prepayments	-20,214	-3,741
Decrease (increase) in other current assets	-329	-352
Total changes in operating assets	-47,476	693
Increase (decrease) in accounts payable	-5,796	8,016
Increase (decrease) in accounts payable to related parties	-40	4 0 10
Increase (decrease) in other payable	1,090	-1,242
Increase (decrease) in other current liabilities	-3,367	3,102
Increase (decrease) in net defined benefit liability	-39	103
Total changes in operating liabilities	-8,152	9,983
Total changes in operating assets and liabilities	-55,628	10,676
Total adjustments	-21,414	26,686
Cash inflow (outflow) generated from operations	-157,058	-67,051
Income taxes refund (paid)	2,245	-975
Net cash flows from (used in) operating activities	-154,813	-68,026
Cash flows from (used in) investing activities		
Acquisition of investments in debt instrument without active market	-250,517	-870,035
Proceeds from disposal of investments in debt instrument without active market	591,444	1,155,502
Acquisition of financial assets at cost	-20,000	0
Acquisition of property, plant and equipment	-117,286	-42,471
Increase in refundable deposits	439	-872
Acquisition of intangible assets	-2,036	C
Increase in other financial assets	-21,301	-9,063
Decrease in other financial assets	12,593	0
Increase in prepayments for business facilities	-49,516	-1,275
Interest received	6,519	10,584
Net cash flows from (used in) investing activities	150,339	242,370
Cash flows from (used in) financing activities		
Exercise of employee share options	5,409	11,790
Payments to acquire treasury shares	0	-87,611
Net cash flows from (used in) financing activities	5,409	-75,821
Effect of exchange rate changes on cash and cash equivalents	0	C
Net increase (decrease) in cash and cash equivalents	935	98,523
Cash and cash equivalents at beginning of period	305,619	238,854
Cash and cash equivalents at end of period	306,554	337,377
Cash and cash equivalents reported in the statement of financial position	306,554	337,377
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Financial Statement — Statements of Changes in Stockholders' Equity

Provided by: Mycenax Biotech Inc. Finacial year: Yearly Unit: NT\$ thousand

20	16/09/	30	S	tat	em	ent	of	Sto	ckh	olo	lers'	Equ	uity	,

e Others Total other equity interest	t Treasury shares Total equity
0 0	J -87,611 1,454,214
0 0	J -87,611 1,454,214
0 0	J 0 -135,912
0 0	0 0
0 0	J 0 -135,912
0 0	J 0 14,939
0 0	J 0 -120,973
0 0	J -87,611 1,333,241
	0 0 0

Accounting Title	ordinary share Advance receip	ots for share capital Total s	share capital Ca	pital surplus Unappropriated	l retained earnings (accumulated deficit) Total re	etained earnings Exchange	e differences on translation of foreign financial statements	Gains (losses) from investments in equity instruments measured at fair value t	hrough other comprehensive income Unro	realized gains (losses) on available-for-sale financial assets G	ains (losses) on effective portion of cash flow hed	dges Gains (losses) on effective portion of hedges of net investments in foreign operat	tions Equity related to non-current assets classified as held for sale Other	ers Total other equity inter	rest Treasury share	res Total equit
Equity at beginning of period Effects of retrospective application and retrospective restatement	1,109,260	1,660	1,110,920	614,121	-87,935	-87,935	0		0	0		0	0	0	0	0 1,637,100
Effects of retrospective application and retrospective restatement	0	0	0	0	0	0	0		0	0		0	0 0	0	0	0 (
Equity at beginning of period after adjustments	1,109,260	1,660	1,110,920	614,121	-87,935	-87,935	0		0	0		0	0 0	0	0	0 1,637,10
Profit (loss)	0	0	0	0	-94,209	-94,209	0		0	0		0	0	0	0	0 -94,209
Other comprehensive income	0	0	0	0	0	0	0		0	0		0	0	0	0	0 (
Total comprehensive income Purchase of treasury share Share-based payments Total increase (decrease) in equity	0	0	0	0	-94,209	-94,209	0		0	0		0	0	0	0	0 -94,209
Purchase of treasury share	0	0	0	0	0	0	0		0	0		0	0	0	0 -87,6	ò11 -87,611
Share-based payments	4,135	3,490	7,625	4,601	0	0	0		0	0		0	0	0	0	0 12,226
Total increase (decrease) in equity	4,135	3,490	7,625	4,601	-94,209	-94,209	0		0	0		0	0	0	0 -87,6	ò11 -169,594
Equity at end of period	1,113,395	5,150	1,118,545	618,722	-182,144	-182,144	0		0	0	_	0	0	0		,611 1,467,512